CINECA IRIS Institutional Research Information System

LA MOTTA, CONCETTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.053
AS - Asia 8.083
EU - Europa 7.804
SA - Sud America 1.096
AF - Africa 356
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 1
Totale 34.429
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.576
IT - Italia 3.018
SG - Singapore 2.477
CN - Cina 2.208
SE - Svezia 1.441
HK - Hong Kong 1.184
BR - Brasile 890
VN - Vietnam 738
DE - Germania 729
BG - Bulgaria 492
TR - Turchia 452
GB - Regno Unito 401
CA - Canada 370
FR - Francia 359
FI - Finlandia 283
AT - Austria 271
RU - Federazione Russa 251
IN - India 237
JP - Giappone 185
UA - Ucraina 163
KR - Corea 108
CI - Costa d'Avorio 99
CH - Svizzera 82
BD - Bangladesh 73
NG - Nigeria 72
NL - Olanda 71
PK - Pakistan 65
MX - Messico 62
IQ - Iraq 50
PL - Polonia 50
AR - Argentina 45
ID - Indonesia 45
SA - Arabia Saudita 45
BE - Belgio 40
VE - Venezuela 40
ZA - Sudafrica 39
ES - Italia 35
CO - Colombia 34
AU - Australia 32
MA - Marocco 31
EC - Ecuador 29
UZ - Uzbekistan 29
JO - Giordania 22
SN - Senegal 22
IE - Irlanda 21
MY - Malesia 19
EG - Egitto 18
KE - Kenya 17
PE - Perù 17
CZ - Repubblica Ceca 16
DZ - Algeria 15
AZ - Azerbaigian 14
GR - Grecia 14
PH - Filippine 14
CL - Cile 13
UY - Uruguay 13
IR - Iran 12
KZ - Kazakistan 11
LT - Lituania 11
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
DK - Danimarca 9
JM - Giamaica 9
LB - Libano 9
TH - Thailandia 9
TN - Tunisia 9
TW - Taiwan 9
AL - Albania 8
IL - Israele 8
CR - Costa Rica 7
NO - Norvegia 7
PS - Palestinian Territory 7
RS - Serbia 7
NP - Nepal 6
OM - Oman 6
SY - Repubblica araba siriana 6
ET - Etiopia 5
GE - Georgia 5
HN - Honduras 5
PA - Panama 5
PT - Portogallo 5
AO - Angola 4
KH - Cambogia 4
NZ - Nuova Zelanda 4
TT - Trinidad e Tobago 4
BJ - Benin 3
BO - Bolivia 3
CG - Congo 3
DO - Repubblica Dominicana 3
LY - Libia 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
BN - Brunei Darussalam 2
CY - Cipro 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
LC - Santa Lucia 2
LK - Sri Lanka 2
Totale 34.383
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.634
Ashburn 1.601
Singapore 1.433
Ann Arbor 1.361
Houston 1.227
Hong Kong 1.162
Fairfield 1.065
Chandler 939
San Jose 926
Serra 883
Santa Clara 833
Dallas 827
Milan 560
Beijing 493
Sofia 489
Seattle 454
Shanghai 448
Wilmington 409
New York 362
Cambridge 356
Izmir 308
Los Angeles 269
Ottawa 267
Boardman 261
Princeton 230
Jacksonville 211
Vienna 199
Lawrence 192
Lauterbourg 178
Dong Ket 168
Hefei 168
Nanjing 163
Medford 158
Ho Chi Minh City 157
London 156
Tokyo 153
Council Bluffs 139
Frankfurt am Main 126
Rome 121
Des Moines 116
Hanoi 104
Helsinki 103
Seoul 103
Istanbul 102
Abidjan 99
Dearborn 89
Munich 88
Rho 85
Buffalo 77
São Paulo 76
Florence 75
Redondo Beach 73
Pisa 71
Chicago 70
Lagos 69
Bremen 62
Redwood City 56
Columbus 55
Lucca 52
The Dalles 52
Boulder 51
San Diego 51
Bern 49
Nanchang 48
Düsseldorf 44
Brussels 40
Shenyang 39
Warsaw 38
Fuzhou 37
Jüchen 36
Kunming 36
Pune 35
Toronto 33
Hebei 32
San Francisco 32
Belo Horizonte 31
Marseille 31
Ogden 31
Falls Church 30
Orem 30
Rio de Janeiro 28
Washington 28
Baghdad 26
Nuremberg 26
Tashkent 26
Zurich 26
Chennai 25
Phoenix 25
Guangzhou 23
Changsha 22
Dakar 22
Denver 21
Haiphong 21
New Delhi 21
Turku 21
Amman 20
Mumbai 20
Jakarta 19
Johannesburg 19
Nürnberg 19
Totale 23.975
Salva come PNG Salva come JPEG
Nome #
Derivati isoindolici come attivatori di AMPK 538
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 414
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 373
Preparation of isoindoline derivatives for use as AMPK activators 346
Soyasaponins from Zolfino bean as aldose reductase differential inhibitors 286
Benzofuroxane Derivatives as Multi Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies 278
Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors, 272
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 254
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 252
Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors 252
Derivati benzofuranici come attivatori di AMPK 250
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 247
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides 243
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: a New Class of Selective Aldose Reductase Inhibitors 236
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 236
Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII 231
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 228
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 227
Functional Studies in the Year of Pulses: the case of Zolfino landraces (Phaesolus vulgaris L.) 226
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: A New Class of Selective Aldose Reductase Inhibitors 222
Hemp (Cannabis sativa L.) flour: an active ingredient for the formulation of nutritious, flavorful and affordable foods. 222
Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors 220
How Reliable Are Current Docking Approaches for Structure-based Drug Design? Lessons from Aldose Reductase 218
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 215
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: Tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands 212
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 212
Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the γ-Aminobutyric Acid-A (GABAA) α2 Benzodiazepine Receptor 210
Complexing the Marine Sesquiterpene Euplotin C by Means of Cyclodextrin-Based Nanosponges: A Preliminary Investigation 209
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A New Class of Selective A1 Adenosine Receptor Antagonists 208
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of non-camptothecin Topoisomerase I (Top1) inhibitors 208
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A(2B) Adenosine Receptor Antagonists. 207
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 205
A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis 203
Evidence for a Novel Binding Site Conformer of Aldose Reductase in Ligand-Bound State 202
Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects 201
Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands 198
Studies in search for selective ligands for GABAA/BzR receptor subtypes: synthesis and biological evaluation of 4'-modified N-(benzyl)indol-3-ylglyoxylamides 197
Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity 197
New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors 197
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists 194
2-(Benzimidazol-2-yl)quinoxalines: A Novel Class of selective Antagonists at Human A1 and A3 Adenosine Receptors Designed by 3D Database Searching 194
Benzothiopyranoindole-Based Antiproliferative Agents: Synthesis, Cytotoxicity, Nucleic Acids Interaction, and Topoisomerases Inhibition Properties. 194
Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents 194
Refinement of Structure-activity Relationships of the Triazinobenzimidazole A1AR Antagonists 193
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications 193
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A(2B) adenosine receptor antagonists 193
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 193
Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening 191
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 190
Synthesis of a Novel Purine-Containing Heterocyclic Ring System: 8,10-Dimethylindolo[2',3':5,6][1,2,4]triazino[4,3-f]purine-9,11(8H,10H,13H)dione 190
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 189
Synthesis of novel 1-aryl[1]benzoxepino[5,4-c]pyrazole and [1]benzoxepino[5,4-d]pyrimidine derivatives 188
Synthesis and functional evaluation of novel aldose reductase inhibitors bearing a spirobenzopyran scaffold 188
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 187
“Synthesis and antiproliferative evaluation of new substituted Benzothiopyrano[4,3-c] condensed ring systems” 187
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 186
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 186
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs 185
Novel Pyrazolo[3,4-d]pyrimidine Derivatives as ATP-competitive Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase 183
Novel N(2)-Substituted Pyrazolo[3,4-d]pyrimidine Adenosine A(3) Receptor Antagonists: Inhibition of A(3)-Mediated Human Glioblastoma Cell Proliferation (dagger) 183
Synthesis of Purinobenzodiazepine and Purinobenzotriazocine derivatives, two new heterocyclic ring systems. 183
Preparation of benzofuran derivatives for use as AMPK activators 182
Novel, Highly Potent Aldose Reductase Inhibitors:Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives 181
Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study 181
A New Approach to Control the Enigmatic Activity of Aldose Reductase 180
Effects of the new aldose reductase inhibitor benzofuroxane derivative bf-5m on high glucose induced prolongation of cardiac qt interval and increase of coronary perfusion pressure 180
Novel Potent and Selective Human Adenosine A3 Receptor Antagonists Containing the Pyrazolo[3,4-d]pyrimidine Ring System. Synthesis and Biological Evaluation 179
Synthesis of novel pyrido[3',2':5,6]thiopyrano[3,2-b]indol-5(6H)-ones and 6H-pyrido[3',2':5,6]thiopyrano[4,3-b]quinolines,two new heterocyclic systems. 178
FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells 174
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 173
A 2,3-diphenylpyrido[1,2-a] pyrimidin-4-one derivative inhibits specific angiogenic factors induced by TNF-α 173
Novel treatments for anaplastic thyroid carcinoma 172
Nuovi derivati acidi acetici quali potenti inibitori dell’Aldoso Reduttasi 171
Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors 170
Geometrically Constrained Derivatives of Indolylglyoxylamides as Ligands Binding the GABAA/BzR Complex. 169
Aldose reductase inhibitors: 2013-present 169
Synthesis and Biological Evaluation of Pyrido[1,2-d]pyrimidin-4-one Derivatives as Novel Aldose Reductase Inhibitors Exhibiting Antioxidant Activity 167
A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): different recognition of bovine and human binding sites 167
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model 166
Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents 166
Imidazo[1,2- a]pyridine derivatives as aldehyde dehydrogenase inhibitors: Novel chemotypes to target glioblastoma stem cells 166
Pyrazolo[3,4,-d]pyrimidine-4-one Derivatives as Novel and Potent Inhibitors of Adenosine Deaminase 165
Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands 165
Small Molecules Containing the Benzo[d]isotiazole Ring System as Novel ATP-Competitive Inhibitors of Epidermal Growth Factor Receptor protein Tyrosine Kinase 164
Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview 163
Derivati a nucleo benzo[d]isotiazol-3(2H)-one-1,1-diossido e loro impiego nel trattamento di tumori 163
Spirohydantoin Derivatives of Thiopyrano[2,3-b]pyridin-4(4H)-one as Potent in Vitro and in Vivo Aldose Reductase Inhibitors 162
Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein 162
Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors 161
Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists 161
Derivati spiroidantoinici del Tiopirano[2,3-b]piridin-4(4H)-one quali potenti inibitori dell’aldoso reduttasi 160
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors 160
Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies 160
Refinement of the translocator protein pharmacophore/receptor model via structure-activity relationships of novel N,N-dialkylindolylglyoxylamides 159
Synthesis of New Heterocyclic Ring Systems via [1,3,5]Triazino[1,2-a]benzimidazole Derivatives 159
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders 159
2-(phenylsulphonamido)-pyrazole derivatives as carbonic anhydrase inhibitors 158
Microwave-assisted Suzuki Coupling in Aqueous Media: a Useful Tool for the Synthesis of 3-Arylindazole Derivatives 156
Novel Aldose Reductase Acetic acid Inhibitors Bearing a Five Membered heterocyclic core 156
Totale 20.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.913
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021373 0 0 0 0 0 0 0 0 0 0 0 373
2021/20222.579 61 171 117 205 448 315 63 133 114 69 174 709
2022/20233.392 471 572 256 303 376 433 67 230 466 21 151 46
2023/20242.302 288 258 279 180 327 430 87 47 32 66 69 239
2024/20256.883 62 264 98 424 743 702 517 359 613 871 677 1.553
2025/20267.787 513 899 945 673 762 630 1.319 378 546 758 345 19
Totale 34.982